OBJECTIVE: To compare the effects of dydrogesterone and calcium plus vitamin D in women with severe premenstrual syndrome (PMS). METHOD: In this randomized, double-blind, placebo-controlled study, 180 Shiraz University students with PMS used questionnaires daily to rate their symptoms for 2 menstrual cycles. Then, the students were randomly assigned to take a tablet containing either 5 mg of dydrogesterone, 500 mg of calcium plus 200 mg of vitamin D, or a placebo twice daily from the 15th to the 24th day of the cycle for 2 more cycles, and to use the same questionnaires during the intervention cycles. The collected data were then analyzed by repeated-measurement design and multilevel modeling tests. RESULT: Treatment with dydrogesterone or calcium plus vitamin D decreased symptom severity in a similar way (by 4.64% and 4.20%, respectively) and placebo was associated with a 3.42% decrease. CONCLUSION: Treatment with dydrogesterone or calcium plus vitamin D had a similar effect on symptom severity in women with PMS.
RCT Entities:
OBJECTIVE: To compare the effects of dydrogesterone and calcium plus vitamin D in women with severe premenstrual syndrome (PMS). METHOD: In this randomized, double-blind, placebo-controlled study, 180 Shiraz University students with PMS used questionnaires daily to rate their symptoms for 2 menstrual cycles. Then, the students were randomly assigned to take a tablet containing either 5 mg of dydrogesterone, 500 mg of calcium plus 200 mg of vitamin D, or a placebo twice daily from the 15th to the 24th day of the cycle for 2 more cycles, and to use the same questionnaires during the intervention cycles. The collected data were then analyzed by repeated-measurement design and multilevel modeling tests. RESULT: Treatment with dydrogesterone or calcium plus vitamin D decreased symptom severity in a similar way (by 4.64% and 4.20%, respectively) and placebo was associated with a 3.42% decrease. CONCLUSION: Treatment with dydrogesterone or calcium plus vitamin D had a similar effect on symptom severity in women with PMS.
Authors: Tracy Nevatte; Patrick Michael Shaughn O'Brien; Torbjorn Bäckström; Candace Brown; Lorraine Dennerstein; Jean Endicott; C Neill Epperson; Elias Eriksson; Ellen W Freeman; Uriel Halbreich; Khalid Ismail; Nicholas Panay; Teri Pearlstein; Andrea Rapkin; Robert Reid; David Rubinow; Peter Schmidt; Meir Steiner; John Studd; Inger Sundström-Poromaa; Kimberly Yonkers Journal: Arch Womens Ment Health Date: 2013-04-27 Impact factor: 3.633
Authors: G Michael Allan; Lynda Cranston; Adrienne Lindblad; James McCormack; Michael R Kolber; Scott Garrison; Christina Korownyk Journal: J Gen Intern Med Date: 2016-03-07 Impact factor: 5.128
Authors: Elizabeth R Bertone-Johnson; Brian W Whitcomb; Janet W Rich-Edwards; Susan E Hankinson; JoAnn E Manson Journal: Am J Epidemiol Date: 2015-11-24 Impact factor: 4.897
Authors: Seetal Dodd; Gin S Malhi; John Tiller; Isaac Schweitzer; Ian Hickie; Jon Paul Khoo; Darryl L Bassett; Bill Lyndon; Philip B Mitchell; Gordon Parker; Paul B Fitzgerald; Marc Udina; Ajeet Singh; Steven Moylan; Francesco Giorlando; Carolyn Doughty; Christopher G Davey; Michael Theodoros; Michael Berk Journal: Aust N Z J Psychiatry Date: 2011-09 Impact factor: 5.744
Authors: Bayan A Obeidat; Haifa A Alchalabi; Khalid K Abdul-Razzak; Mudhaffar I Al-Farras Journal: Int J Environ Res Public Health Date: 2012-11-16 Impact factor: 3.390
Authors: Elizabeth R Bertone-Johnson; Susan E Hankinson; Nancy G Forger; Sally I Powers; Walter C Willett; Susan R Johnson; JoAnn E Manson Journal: BMC Womens Health Date: 2014-04-12 Impact factor: 2.809